MEMORANDUM
The individual plaintiffs in this consolidated class action seek, pursuant to Federal Rule of Civil Procedure 23, judicial approval of a negotiated settlement agreement in which the defendants agreed to pay class members the sum of $22 million. Plaintiffs’ lead counsel have filed a joint petition for reimbursement of expenses and an award of attorneys’ fees. As part of the latter application, counsel also request that special awards be conferred upon the class representatives. An appropriately noticed public hearing was held on October 3, 1990. For the reasons that follow, the Court will grant both motions.
I.
A.
This litigation consists of eight class action suits instituted under Section 11 of the Securities Act of 1933, 48 Stat. 74, 15 U.S.C. § 77k, Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934, 48 Stat. 891, 15 U.S.C. §§ 78j(b) & 78t(a), and Securities and Exchange Commission Rule 1 Ob-5, 17 C.F.R. § 240.10b-5. The defendants are SmithKline Beckman Corporation, which is now known as SmithKline Beecham Corporation, members of its Board of Directors, Henry Wendt, George Ebright, and Kenneth Kermes. The Court consolidated the separate lawsuits for pretrial purposes and, over the defendants' opposition, certified as a class all persons (excluding the defendants and their successors, affiliates, and family members) who purchased SmithKline common stock from March 13, 1987 through September 28, 1988.
The plaintiffs alleged in their complaint that the individual defendants, acting in their capacities as officers or directors of SmithKline, made misrepresentations of material fact in the company’s 1986, 1987, and 1988 shareholder reports, in its 10-K reports 1 filed with the SEC in 1987, and in various public statements. More precisely, the plaintiffs charged that the defendants fraudulently had fostered the expectation that SmithKline would continue its ten percent rate of annual growth in operating earnings throughout the 1980s. This was ostensibly despite the fact that the market *527 for the drugs Tagamet and Dyazide, the company’s principal sellers, was eroding, that SmithKline lacked any new substantial products which could be introduced in the short term, and that price increases for existing drugs could not generate sufficient revenues to compensate for the market share decline of Tagamet and Dyazide, let alone achieve the anticipated level in corporate growth.
In consequence, the plaintiffs asserted, the market price of SmithKline common stock was artificially inflated from March 13, 1987 until the company’s public announcements of June 16, 1988 and September 27, 1988. On June 16th, SmithKline forecasted that its operating earnings for the second and third quarters of 1988 would fall approximately twenty-five percent below 1987 quarterly earnings. The per share price of common stock dropped twenty percent, to $45.75, in response to the company’s revelation. According to the plaintiffs, however, this was only a partial disclosure of SmithKline’s true financial condition because the defendants continued to misrepresent the nature and expense of its global restructuring plan and had not related the full gravity of the company’s market share losses.
On September 27th, the defendants allegedly reported that, as part of its business restructuring strategy, SmithKline would lay off some 1600 employees, close its Philadelphia manufacturing plant, and sell its subsidiaries, for a one-time charge of $300 to $400 million in 1988. The price of the company’s common stock declined $3.00 per share. A month later, SmithKline revealed that it would take a pre-tax charge of $398.3 million in the third quarter. This represented a net loss of $195.5 million, which the defendants purportedly blamed on lethargic sales of Tagamet and Dyazide.
After class certification, the plaintiffs embarked on extensive discovery, which lasted for over a year. SmithKline produced several hundred thousand pages of documents. A comparable magnitude of documents were divulged, pursuant to subpoena duces tecum, by non-parties, including Peat Marwick Main & Company and Coopers & Lybrand, which had served as SmithKline’s auditors during the relevant period. Plaintiffs’ counsel served two sets of interrogatories on all defendants and conducted depositions of nine SmithKline officers and employees. Attorneys for the class also retained experts conversant in accounting and investment banking to assist in their evaluation of discovery materials. The parties began settlement negotiations in October 1989. The defendants requested, and the plaintiffs provided, a comprehensive analysis of evidence supportive of liability to class members. After several months of discussion, the litigants entered into a written Stipulation of Settlement on August 10, 1990.
The Court then approved a notice of hearing on the proposed settlement agreement. The notice related the terms of the Stipulation, indicated that counsel for the plaintiffs would petition the Court for an award of fees comprising up to 30% of the settlement fund, stated that the Court had scheduled a hearing to consider the appropriateness of the Stipulation, and invited class members to file written comments in support of or in opposition to the Stipulation of Settlement. The notice was mailed to all class members known to the parties, and a summary of it was published in The Wall Street Journal, The New York Times, The Philadelphia Inquirer, and the Financial Times.
B.
As provided by the Stipulation, the defendants paid into an escrow account $22 million, which, together with interest earned less deductions for attorneys’ fees and proper expenses, constitutes the net settlement fund that will be distributed to class members whose claims are approved as valid and timely. Paragraph 10 of the Stipulation enunciates the procedures that class members must follow to become authorized claimants against the net settlement fund. Each class member must submit a proof of claim, along with supporting documentation, to the claims administrator. Claims rejected by the administrator are *528 subject to review by plaintiffs’ lead counsel, and, ultimately, this Court.
A two-step process, which endeavors to tailor the shareholder’s recovery to his or her economic injury, regulates allocation of the net settlement fund. First, the amount of an authorized claimant’s recognized loss depends on when that individual purchased or sold SmithKline securities. The various formulae set forth in the Stipulation are as follows:
(i)(a) With respect to shares of SmithK-line common stock purchased from March 13, 1987 through June 15, 1988, and held after the close of business on June 15, and with respect to shares purchased on June 16, 1988, Recognized Loss is defined as the amount paid for such shares (excluding commission), less the number of such shares multiplied by $44.06, the closing price for SmithKline common stock on September 28, 1988;
(b) with respect to shares of SmithKline common stock purchased from June 17, 1988 through September 27, 1988, and held after the close of business on September 27, and with respect to shares purchased on September 28, 1988, Recognized Loss is defined as the amount paid for such shares (excluding commissions), less the number of such shares multiplied by $44.06; and
(c) with respect to shares of SmithKline common stock purchased from March 13, 1987 through June 15, 1988 and not held after the close of business on June 15, 1988, and with respect to shares purchased from June 17, 1988, through September 27, 1988, and not held after the close of business on September 27, 1988, Recognized Loss is defined as one-third (33% percent) of the following: the amount paid for such shares (excluding commissions) less the amount realized (net of commissions) from the sale of such shares (based on trade date, not settlement date).
Stip. of Settlement ¶ 9(b). Second, the net settlement fund will be divided by the total recognized loss of all claimants to arrive at a distribution ratio. Each authorized claimant’s share of the net settlement fund is then ascertained by multiplying the distribution ratio by that claimant’s recognized loss.
II.
The standard for approval of a proposed class action settlement is well known. The Court must ascertain whether the submitted compromise is “fair, adequate, and reasonable.”
Walsh v. Great Atlantic & Pacific Tea Co.,
First, further litigation in this case would present issues that would be costly to resolve, would result in protracted proceedings, and would pose acute risks for all concerned. Section 11 of the Securities Act authorizes any person acquiring a security covered by a registration statement that contains a misrepresentation or omission of material
2
fact to bring suit against individuals who signed the registration statement or served as directors of the issuer. Because this provision was “designed not so
*529
much to compensate the defrauded purchaser as to ... deter negligence by providing a penalty for those who fail in their duties,”
Globus v. Law Research Serv.,
In contrast, Section 10(b) of the Exchange Act and Rule 10b-5 thereunder forbid the making of untrue or incomplete statements of material fact in connection with the purchase or sale of securities. Unlike Section 11,
see Kusner v. First Pennsylvania Corp.,
“[Stockholder litigation is notably difficult and notoriously uncertain” even in the best of circumstances.
Lewis v. Newman,
The determination of whether the classes sustained damages and to what degree would entail additional litigation risks and burdens. The measure of damages in a Section 10(b) action is the out-of-pocket loss suffered by each aggrieved shareholder. Both parties would have to utilize, at great expense, experts to hypothesize what the fair value of the stock would have been in the absence of the claimed fraud.
See Affiliated Ute Citizens of Utah v. United States,
Second, the reaction of the class to the proffered settlement is perhaps the most significant factor to be weighed in considering its adequacy, particularly when the relief is expressed in monetary terms. The Court ordered that class members be notified by mail and publication, and not one has lodged an objection to the settlement’s terms. Both the utter absence of objections and the nominal number of shareholders who have exercised their right to opt out of this litigation militate strongly in favor of approval of the settlement.
Third, as explained previously, the plaintiffs secured a voluminous amount discovery material and thoroughly analyzed it. Given that attorneys for the classes already have expended some 11,000 hours in the prosecution of this action, there is little reason to believe that further proceedings would generate new and worthwhile information. Counsel therefore are fully cognizant of the relative merits and deficiencies of their clients’ positions. A settlement at this time represents, for both sides, a significant savings of trial and appeals costs.
Although the danger of class decertification at trial appears marginal, the plaintiffs are at risk that elasswide relief might not be available. More importantly, realization of the limited prospect of decertification would carry grave consequences. Because the total number of SmithKline shares outstanding at any given time is between 105 and 130 million, many of which may have been held by different persons during the class period, revocation of certification would spawn such a multiplicity of separate suits that the ensuing burden on the legal system is incalculable. Further, absent a class action mechanism, those shareholders who incurred minimal losses effectively would lack legal recourse to vindicate their claims,
see Roper v. Consurve, Inc.,
The Court also has considered the defendants’ ability to withstand a greater judgment. There is no evidence in the record that SmithKline would be unable to satisfy a larger damages award. The proposed settlement, however, obviates the peril that class members, after undertaking the considerable expense of trial, will obtain an even more sizeable award against the defendants and then discover that they cannot satisfy the judgment.
Last, the Court has evaluated the range of reasonableness of the settlement in light of all the risks associated with litigation. Experienced counsel for both parties, negotiating at arm’s-length and possessing all pertinent information, have recommended the present settlement, and their views are entitled to respect. Plaintiffs’ reliance on circumstantial and accretive evidence to establish scienter and the inherently speculative nature of losses incurred place severe obstacles to proving both liability and damages. Although an award in excess of the settlement value might be a possibility at trial, the settlement is well within the range of reasonableness identified by the Third Circuit in Girsh. In sum, the relative considerations weigh in favor of the *531 proposed Stipulation of Settlement, and it accordingly will be approved.
III.
A.
The Supreme Court has recognized that a “litigant who recovers a common fund for the benefit of persons other than himself or his client is entitled to a reasonable attorney’s fee from the fund as a whole.”
Boeing Co. v. Van Gemert,
Although it is well established that attorneys’ fees may be drawn from a fund in court, there is some controversy regarding the proper method by which the amount of compensation should be calculated. Until 1973, the size of the fee award in both common fund cases and statutory fee shifting cases was left to the court’s discretion. “Awards often reflected what the court believed was a ‘reasonable percentage’ of the amount recovered.”
Court Awarded Attorney Fees: Report of the Third Circuit Task Force
(1985),
reprinted in
Responding to these criticisms, the Third Circuit, in
Lindy I
and
Lindy II,
developed the lodestar method of setting fees. This approach is composed of two steps. First, the court multiplies the hours spent on the case by a reasonable hourly rate of compensation for each attorney involved. Second, the court adjusts that figure to reflect the contingent nature of the litigation, the difficulty of the issues involved, and the quality of the attorney’s work.
In re Fine Paper Antitrust Litigation,
With the advent of
Lindy,
courts soon began applying the lodestar formulation to both equitable fund and statutory fee cases “without any real analysis of the propriety of doing so,”
Task Force Report,
Moreover, the Supreme Court not only has distinguished between fund-in-court and statutory fee cases, it also has recognized the propriety of employing the percentage of recovery method in the common fund context. • “Unlike the calculation of attorney’s fees under the ‘common fund doctrine,’ where a reasonable fee is based on a percentage of the fund bestowed on the class, a reasonable fee under [fee shifting statutes] reflects the amount of attorney time reasonably expended on the litigation.”
Blum v. Stenson,
B.
Because the instant suit involves a straightforward common fund, certain principles guide the disposition of plaintiffs’ counsel’s motion. First, the district court retains discretion to calculate the fee.
Task Force Report,
The Court has examined both the fee petition submitted by plaintiffs’ counsel and the entire record of this litigation. Based on that review, the Court concludes *534 that the class members were well served by experienced attorneys who effectively prosecuted a case that presented vexing factual and logistical difficulties, but who nonetheless obtained a highly favorable recovery. Petitioners also brought this action to a close only two years after filing the complaint, despite the problems with which they contended. This is precisely the sort of result that the percentage of recovery fee method is intended to foster and stands as a counterexample to the perennial laments about the slow pace of complex litigation.
Moreover, plaintiffs’ counsel terminated this controversy by settlement and thereby avoided burdening the federal judicial system with a trial and appeals. Because “a prompt and efficient attorney who achieves a fair settlement without litigation serves both his client and the interests of justice,”
McKenzie Constr. Co. v. Maynard,
On the other hand, the percentage of recovery fee should decrease as the size of the common fund increases. The employment of a sliding scale not only was recommended by the Third Circuit Task Force,
Plaintiffs’ counsel also have moved for reimbursement of $202,460 in aggregate costs incurred between inception of the lawsuit and July 31, 1990. A significant portion of that sum was disbursed to experts and consultants, an expense that clearly is compensable even though the action settled, since their testimony would have been indispensable to the plaintiffs’ ease had it proceeded to trial.
See, e.g., Roberts v. S.S. Kyriakoula D. Lemos,
*535 C.
Last, the Court agrees that special awards to the class representatives are appropriate. First, they have rendered a public service by contributing to the vitality of the federal Securities Acts. “Private litigation aids effective enforcement of the securities laws because private plaintiffs prosecute violations that might otherwise go undetected due to the SEC’s limited resources.” Note,
Private Causes of Action for Option Investors Under SEC Rule 10b-5: A Policy, Doctrinal, and Economic Analysis,
100 Harv.L.Rev. 1959, 1963 n. 24 (1987).
Accord Berner v. Lazzaro,
ORDER AND FINAL JUDGMENT
AND NOW, this 29th day of October, 1990, for the reasons set forth in this Court’s Memorandum of October 29, 1990;
IT IS ORDERED that the Stipulation of Settlement dated and filed August 10, 1990 in the above-captioned action, and hereby made a part of this Order, is APPROVED;
AND IT IS FURTHER ORDERED that, this Court having certified this consolidated action as a class action on behalf of a class including all persons who purchased the common stock of SmithKline Beckman Corporation during the period from March 13, 1987, through September 28, 1988, excluding Defendants and certain others and excluding all persons who timely submitted a request to be excluded from the class, pursuant to Rule 23(c)(2) of the Federal Rules of Civil Procedure, who are not bound by any of the terms of this Order, entry of final judgment and approval of the Stipulation of Settlement shall settle all claims alleged in this action between Plaintiffs and the class on the one hand and defendants on the other;
AND IT IS FURTHER ORDERED that all claims alleged in this action are DISMISSED in their entirety on the merits, with prejudice, and without costs to any party and that all complaints filed in these actions, including Plaintiffs’ First and Second Amended Consolidated Complaints, are DISMISSED in their entirety on the merits, with prejudice, and without costs to any party;
AND IT IS FURTHER ORDERED that Plaintiffs and all members of the Class are hereby permanently barred and enjoined from prosecuting in any jurisdiction against any of the released parties, as defined by the Stipulation of Settlement, any and all actions and causes of action, suits or claims of any nature whatsoever, in accordance with the terms of the Stipulation of Settlement;
AND IT IS FURTHER ORDERED that, there being no reason for delay, the Clerk of Court is hereby directed, pursuant to Federal Rule of Civil Procedure 54, to ENTER this Order as a final judgment;
AND IT IS FURTHER ORDERED that plaintiffs’ counsel are jointly AWARDED $5,692,250, in attorneys’ fees and $202,460 in costs, for a total of $5,894,710 to be paid from the common fund established pursuant to the Stipulation of Settlement approved by this Court;
AND IT IS FURTHER ORDERED that each of the following groups of Class Representatives are AWARDED $5000, plus a proportionate share of the interest earned thereon, to be paid from the common fund established pursuant to the Stipulation of Settlement approved by this Court: (i) Rodney B. Shields, (ii) National Ammonia Company, (iii) Robert H. Shenker Keogh Plan/Robert H. Shenker Profit Sharing Plan, (iv) Harris J. Sklar, (v) William R. and Patricia J. Solvible, (vi) Estate of Irwin Berman, (vii) Ellen Denenberg, (viii) Joseph Liberman, and (ix) Steven and Hallie Gold-stein;
*536 AND IT IS FURTHER ORDERED that the balance of the settlement fund, which has a present value of approximately $16,-830,000, plus accrued interest less proper administrative expenses, shall be distributed to authorized claimants pursuant to the terms of the approved Stipulation of Settlement and that jurisdiction over all matters relating to the consummation of the Stipulation of Settlement is reserved in this Court.
Notes
. Section 13 of the Exchange Act, 15 U.S.C. § 78m, mandates that all registered corporations, as defined by Section 12, 15 U.S.C. § 78/(g), provide certain information to the SEC. Form 10-K requires a registrant to submit detailed statements describing, among other matters, its financial affairs. See 17 C.F.R. § 249.310; Amendments to Annual Report Form, Related Forms, Rules, Regulations and Guides, 45 Fed.Reg. 63,630, 63,640-44.
. An identified falsehood or omission is material if it pertains to a matter about which "an average prudent investor ought reasonably to be informed before purchasing” the security. 17 C.F.R. § 230.405(1).
Accord Kubik v. Goldfield,
. One individual, June H. Norman of Los Ange-les, did send an untimely, and obscenity-ridden, diatribe against lawyers, which the Court interprets as an objection to the proposed recovery of fees. Even though the letter was enclosed in a Bear, Stearns & Company envelope, Ms. Norman does not indicate that she has any interest in this suit. Nor does she state what fee she thinks would be reasonable under the circumstances.
